Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 13/20 | 0.48 |
| ▸ | EGFR | P00533 | 3/20 | 0.48 |
| ▸ | ADK | P55263 | 5/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | ABL2 | P42684 | 2/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29588478 | 1.00 | SRC (0.48) | SRCEGFRADKABL1ABL2 | |
| SCHEMBL1442315 | 0.92 | SRC (0.59) | SRCEGFRADKABL1ABL2 | |
| SCHEMBL29588466 | 0.92 | SRC (0.59) | SRCEGFRADKABL1ABL2 | |
| SCHEMBL15345425 | 0.92 | SRC (0.59) | SRCEGFRADKABL1ABL2 | |
| SCHEMBL1442313 | 0.92 | SRC (0.59) | SRCEGFRADKABL1ABL2 | |
| SCHEMBL29588435 | 0.92 | SRC (0.59) | SRCEGFRADKABL1ABL2 | |
| SCHEMBL29589197 | 0.92 | SRC (0.59) | SRCEGFRADKABL1ABL2 | |
| SCHEMBL15516700 | 0.90 | SRC (0.53) | SRCEGFRADKABL1ABL2 | |
| SCHEMBL13858155 | 0.90 | SRC (0.53) | SRCEGFRADKABL1ABL2 | |
| SCHEMBL29503465 | 0.89 | SRC (0.52) | SRCEGFRADKABL1ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109328187-B | Novel compound with FGFR (FGFR) inhibitory activity as well as preparation and application thereof | 中国科学院上海药物研究所 | 2022-04-26 | — | — | CN | disclosed |
| CN-113768935-A | Prophylactic and/or therapeutic agent for immune diseases | 大鹏药品工业株式会社 | 2021-12-10 | — | — | CN | disclosed |
| CN-113683629-A | Substituted heteroaryl compounds, compositions and uses thereof | 北京范恩柯尔生物科技有限公司 | 2021-11-23 | — | — | CN | disclosed |
| CN-107206001-B | Prophylactic and/or therapeutic agent for immune diseases | 大鹏药品工业株式会社 | 2021-09-28 | — | — | CN | disclosed |
| CN-110036014-B | Compound with AXL inhibitory activity and preparation and application thereof | 中国科学院上海药物研究所 | 2021-09-07 | — | — | CN | disclosed |
| US-10894048-B2 | Antitumor drug for intermittent administration of FGFR inhibitor | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-19 | — | — | US | disclosed |
| US-10835536-B2 | Therapeutic agent for FGFR inhibitor-resistant cancer | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-11-17 | — | — | US | disclosed |
| EP-3023101-B1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | TAIHO PHARMACEUTICAL CO LTD (JP) | 2020-08-19 | — | — | EP | disclosed |
| US-20190183897-A1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-06-20 | — | — | US | disclosed |
| EP-3486244-A1 | NEW COMPOUND HAVING FGFR INHIBITORY ACTIVITY AND PREPARATION AND APPLICATION THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-05-22 | — | — | EP | disclosed |
| EP-3023101-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | Taiho Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | disclosed |
| EP-3023100-A1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | Taiho Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | disclosed |
| US-20160136168-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-05-19 | — | — | US | disclosed |
| US-20160115168-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-04-28 | — | — | US | disclosed |
| US-20160115168-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-04-28 | — | — | US | disclosed |
| EP-2947086-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2015-11-25 | — | — | EP | disclosed |
| US-9108973-B2 | 3,5-disubstituted alkynylbenzene compound and salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-18 | — | — | US | disclosed |
| US-20140343035-A1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO.,LTD. (JP) | 2014-11-20 | — | — | US | disclosed |
| EP-2657233-B1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2014-08-27 | — | — | EP | disclosed |
| EP-2657233-A1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2013-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190183897-A1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | FGFR1, FGFR3, FGFR2 | SRC 54/4885EGFR 27/4885ADK 2280/4885 |
| US-20160136168-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | FGFR1, FGFR3, FGFR4 | SRC 48/4885EGFR 14/4885ADK 2126/4885 |
| US-10894048-B2 | Antitumor drug for intermittent administration of FGFR inhibitor | FGFR1, FGFR3, FGFR2 | SRC 54/4885EGFR 27/4885ADK 2280/4885 |
| US-20140343035-A1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | NFXL1, ZFX, CXXC5 | SRC 306/4885EGFR 1467/4885ADK 4572/4885 |
| US-10835536-B2 | Therapeutic agent for FGFR inhibitor-resistant cancer | FGFR1, FGFR3, FGFR4 | SRC 48/4885EGFR 14/4885ADK 2126/4885 |
| US-20160115168-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | BTK, JAK2, SYK | SRC 18/4885EGFR 839/4885ADK 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.